

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
SCHEDULE 13D  
Under the Securities Exchange Act of 1934  
(Amendment No. )\*

ASSEMBLY BIOSCIENCES, INC.  
(Name of Issuer)  
Common Stock, par value \$0.001  
(Title of Class of Securities)  
0453961080  
(CUSIP Number)

Alexander Schornstein  
Camino Capital GmbH  
Kaiser-Friedrich-Allee 2, 52074 Aachen  
Germany  
004915142314669  
(Name, Address and Telephone Number of  
Person

Authorized to Receive Notices and  
Communications)  
October 23, 2023  
(Date of Event which Requires Filing of  
this Statement)  
If the filing person has previously filed  
a statement on Schedule 13G to report the  
acquisition that is the subject of this  
Schedule 13D, and is filing this schedule  
because of 240.13d-1(e), 240.13d-1(f)  
or 240.13d-1(g), check the following box.  
?

Note: Schedules filed in paper format  
shall include a signed original and five  
copies of the schedule, including all  
exhibits. See 240.13d-7 for other  
parties to whom copies are to be sent.

\* The remainder of this cover page shall  
be filled out for a reporting person's  
initial filing on this form with respect  
to the subject class of securities, and  
for any subsequent amendment containing  
information which would alter disclosures  
provided in a prior cover page.  
The information required on the remainder  
of this cover page shall not be deemed to  
be "filed" for the purpose of Section 18  
of the Securities Exchange Act of 1934  
("Act") or otherwise subject to the  
liabilities of that section of the Act  
but shall be subject to all other  
provisions of the Act (however, see the  
Notes).

C  
U  
S  
I  
P  
  
N  
o  
..  
  
0  
4  
5  
3  
9  
6  
1  
0  
8  
0  
  
1  
3

D  
P  
a  
g  
e  
  
2  
  
o  
f  
  
3  
  
P  
a  
g  
e  
s

1  
..

N  
A  
M  
E  
S  
  
O  
F  
  
R  
E  
P  
O  
R  
T  
I  
N  
G  
  
P  
E  
R  
S  
O  
N  
S

A  
l  
e  
x  
a  
n  
d  
e  
r  
  
S  
c  
h  
o  
r  
n  
s  
t  
e  
i

n  
2  
..  
C  
H  
E  
C  
K  
T  
H  
E  
A  
P  
P  
R  
O  
P  
R  
I  
A  
T  
E  
B  
O  
X  
I  
F  
A  
M  
E  
M  
B  
E  
R  
O  
F  
A  
G  
R  
O  
U  
P  
(  
s  
e  
e  
i  
n  
s  
t  
r  
u  
c  
t  
i  
o  
n  
s  
)  
(  
a  
)  
  
?  
(

b )

?

3 ..

S  
E  
C

U  
S  
E

O  
N  
L  
Y

4 ..

S  
O  
U  
R  
C  
E

O  
F

F  
U  
N  
D  
S

(  
s  
e  
e

i  
n  
s  
t  
r  
u  
c  
t  
i  
o  
n  
s  
)

P  
F

5 ..

C  
H  
E  
C  
K

B  
O  
X

I  
F  
  
D  
I  
S  
C  
L  
O  
S  
U  
R  
E  
  
O  
F  
  
L  
E  
G  
A  
L  
  
P  
R  
O  
C  
E  
E  
D  
I  
N  
G  
S  
  
I  
S  
  
R  
E  
Q  
U  
I  
R  
E  
D  
  
P  
U  
R  
S  
U  
A  
N  
T  
  
T  
O  
  
I  
T  
E  
M  
S  
  
2  
(  
d  
)  
  
o  
r  
  
2  
(  
e  
)

?

6 ..

C  
I  
T  
I  
Z  
E  
N  
S  
H  
I  
P

O  
R

P  
L  
A  
C  
E

O  
F

O  
R  
G  
A  
N  
I  
Z  
A  
T  
I  
O  
N

F  
e  
d  
e  
r  
a  
l

R  
e  
p  
u  
b  
l  
i  
c

o  
f

G  
e  
r  
m  
a  
n  
y

N

U  
M  
B  
E  
R  
  
O  
F  
  
S  
H  
A  
R  
E  
S  
  
B  
E  
N  
E  
F  
I  
C  
I  
A  
L  
L  
Y  
  
O  
W  
N  
E  
D  
  
B  
Y  
  
E  
A  
C  
H  
  
R  
E  
P  
O  
R  
T  
I  
N  
G  
  
P  
E  
R  
S  
O  
N  
  
W  
I  
T  
H  
  
7  
..  
  
S  
O  
L  
E  
  
V  
O  
T  
I  
N  
G  
  
P

O  
W  
E  
R  
  
6  
/  
0  
6  
0  
/  
0  
0  
0

8  
..

S  
H  
A  
R  
E  
D

V  
O  
T  
I  
N  
G

P  
O  
W  
E  
R

1  
/  
1  
0  
4  
/  
2  
9  
2

9  
..

S  
O  
L  
E

D  
I  
S  
P  
O  
S  
I  
T  
I  
V  
E

P  
O  
W  
E  
R

0  
0  
/  
0  
0



0

10 ..

SHARED

DISPOSITIVE

POWER

00 / 000

11 ..

AGGREGATE

AMOUNT

BENEFICIALLY

OWN

E  
D  
  
B  
Y  
  
E  
A  
C  
H  
  
R  
E  
P  
O  
R  
T  
I  
N  
G  
  
P  
E  
R  
S  
O  
N  
  
7  
,  
1  
6  
4  
,  
2  
9  
2  
  
1  
2  
..  
  
C  
H  
E  
C  
K  
  
B  
O  
X  
  
I  
F  
  
T  
H  
E  
  
A  
G  
G  
R  
E  
G  
A  
T  
E  
  
A  
M  
O  
U  
N  
T  
  
I  
N  
  
R

O  
W

(  
1  
1  
)

E  
X  
C  
L  
U  
D  
E  
S

C  
E  
R  
T  
A  
I  
N

S  
H  
A  
R  
E  
S  
(  
s  
e  
e

i  
n  
s  
t  
r  
u  
c  
t  
i  
o  
n  
s  
)

?

1  
3  
..

P  
E  
R  
C  
E  
N  
T

O  
F

C  
L  
A  
S  
S

R  
E  
P

R  
E  
S  
E  
N  
T  
E  
D  
  
B  
Y  
  
A  
M  
O  
U  
N  
T  
  
I  
N  
  
R  
O  
W  
  
(  
1  
1  
)  
  
1  
0  
,  
9  
%  
  
1  
4  
.  
.  
  
T  
Y  
P  
E  
  
O  
F  
  
R  
E  
P  
O  
R  
T  
I  
N  
G  
  
P  
E  
R  
S  
O  
N  
  
(  
s  
e  
e  
  
i  
n  
s  
t  
r  
u  
c  
t  
i

O  
n  
s  
)  
  
I  
N

C  
U  
S  
I  
P

N  
O  
..

0  
4  
5  
3  
9  
6  
1  
0  
8  
0

1  
3  
D

P  
a  
g  
e

2

o  
f

3

P  
a  
g  
e  
s

Item 1. Security and Issuer.  
This Schedule 13D (the "Schedule 13D") relates to the common stock, par value \$0.001 per share (the "Common Stock"), of Assembly Biosciences, Inc., a Delaware corporation (the "Issuer"). The Issuer's principal executive offices are located at 331 Oyster Point Blvd., Fourth Floor, South San Francisco, California 94080.

Item 2. Identity and Background.  
(a) This statement is being filed by Alexander Schornstein.  
(b) The principal place of business and

office of Mr. Schornstein is located at Kaiser-Friedrich-Allee 2, 52074 Aachen, Germany.

(c) Mr. Schornstein is self-employed as an entrepreneur and investor.

(d) Mr. Schornstein has, during the last five years, not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) Mr. Schornstein has, during the last five years, not been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is not subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Mr. Schornstein is a citizen of the Federal Republic of Germany.

Item 3. Source or Amount of Funds or Other Consideration.

Mr. Schornstein used personal funds for his investment.

Item 4. Purpose of Transaction.

Mr. Schornstein is an investor in the biotech sector and initially purchased the shares based on his belief that the shares, when purchased, represented an attractive opportunity. The shares of the Issuer currently trade at a discount to its cash/liquidation value although the Issuer itself has recently repeatedly been very optimistic about its future.

Mr. Schornstein has converted to a Schedule 13D as an intend to engage in discussions with the Board of Directors (the ?Board?) and management of the Issuer regarding a variety of matters relating to the Issuer including, among other things, the Issuer's business, operations, expenses, direction and opportunities to enhance value for all shareholders. Mr. Schornstein may also engage in discussion with other shareholders, industry analysts, existing or potential strategic partners or competitors and other third parties regarding the foregoing.

Item 5. Interest in Securities of the Issuer.

As of October 31, 2023, Mr.Schornstein beneficially (directly or indirectly) owned 7,164,292 shares of the Company?s common stock, which constitutes approximately 10,9% of the outstanding common stock.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Mr. Schornstein has no contracts, arrangements, understandings or relationships with respect to securities of the issuer.

Item 7. Material to Be Filed as Exhibits.

Not applicable.

N  
O  
..

0  
4  
5  
3  
9  
6  
1  
0  
8  
0

1  
3  
D

P  
a  
g  
e

3

o  
f

3

P  
a  
g  
e  
s

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

COMPANY  
NAME

/s/  
Alexander  
Schornstein

Alexander  
Schornstein

October 31,  
2023